Table 1.
Targeted sequencing of MYD88 L265P for 14 PCNSL samples
| Mutation ratio of MYD88 L265P (%) | ||||||
|---|---|---|---|---|---|---|
| Tumors | Cell‐free DNAs in serum | |||||
| NGS | ddPCR | NGS | ddPCR | |||
| VAF (%) | Reads showing the mutation/total reads | FA (%) | VAF | Reads showing the mutation/total reads | FA (%) | |
| TP73 | 43.2 | 8584/19870 | ND | 0 | 0/19996 | 0 |
| TP87 | 65.5 | 13070/19954 | ND | 0 | 0/19930 | 0.40 |
| TP89 | 35.1 | 6979/19882 | ND | 0 | 0/19981 | 0.19 |
| TP90 | 40.9 | 8137/19895 | ND | 0 | 0/19980 | 0.09 |
| TP92 | 53.3 | 10534/19763 | ND | 0 | 0/19985 | 0.10 |
| TP94 | 61.3 | 12233/19956 | ND | 0 | 0/19948 | 0.38 |
| TP95 | 36.4 | 7230/19862 | ND | 0 | 0/19963 | 0.14 |
| TP96 | 56.1 | 11122/19825 | ND | 0 | 0/19972 | 0.47 |
| TP98 | 88.7 | 17736/19993 | 87 | 0 | 0/19987 | 0 |
| TP99 | 56.6 | 11299/19974 | 55.9 | 0 | 0/19994 | 0.69 |
| TP100 | 75.2 | 15025/19980 | 79 | ND | ND | 0 |
| TP101 | 9.2 | 1844/19988 | 10.5 | 0 | 0/12560 | 0 |
| TP102 | 43 | 7260/16868 | 38.3 | 0 | 0/19991 | 0 |
| TP103 | 19.7 | 3928/19973 | 17.1 | 0 | 0/19989 | 0 |
ddPCR, droplet digital PCR; FA, fractional abundance; ND, not done; NGS, next‐generation sequencing; PCNSL, primary central nervous system lymphoma; VAF, variant allele frequency.